News

In addition to the high efficacy, the results showed an excellent tolerability and safety profile with low risk of hypoglycemia or other side effects (such as gastrointestinal discomfort)

The availability of Karbinal ER provides physicians with a new, effective and easy to use treatment option for children with seasonal and perennial allergic rhinitis that need symptomatic

The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the

As part of the deal, CMC will develop a CHEF1 production cell line and process for manufacture of MVI’s monoclonal antibody, targeting circumsporozoite protein (CSP), for use by

SinoVeda Canada has signed an exclusive license agreement with Exzell Pharma to commercialize Effecti-Cal in Canada, the US, Australia and New Zealand. The agreement includes upfront and milestone

Earlier in January, the company entered into a world-wide collaboration with UCB to develop and commercialize NPT200-11 in all indications. So far, the company has secured $20.5m of

The trial met its primary endpoint, showing that venetoclax monotherapy resulted in a clinically meaningful reduction in the number of cancer cells in a pre-defined proportion of people

Vonapanitase is an investigational drug that may prolong the patency and reduce the failure of hemodialysis vascular access in patients with CKD. The new trial complements the first

The earlier collaboration between the two firms focused on the discovery of new treatments for neuropsychiatric disorders, while the new three-year deal will focus on investigating new medicines